Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy

Česká verzia

Authors: I. Richter ^1,2; J. Dvořák ² ; V. Hejzlarová ¹; J. Chalupa ¹; M. Sochor ¹; I. Stankuš ¹; L. Barsová ¹; M. Holikova ¹; J. Forster ³; J. Bartoš ¹
Authors place of work: Onkologické oddělení, Krajská nemocnice Liberec, a. s. ¹; Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha ²; Onkologické oddělení, Oblastní nemocnice Jičín, a. s. ³
Published in the journal: Klin Onkol 2016; 29(2): 127-132
Category: Původní práce
doi: https://doi.org/10.14735/amko2016127

Summary

Aim:
Enzalutamide and abiraterone represent new therapeutical options in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the presented study was retrospective analysis of clinical experience and efficacy of enzalutamide or abiraterone in the postchemo indication in patients with mCRPC.

Patients and Methods:
A total of 32 mCRPC patients were evaluated. All patients received one or more lines of chemotherapy. Twenty-three patients were treated by enzalutamide, nine patients were treated by abiraterone. We defined two parameters: over all survival and progression-free survival.

Results:
The median follow-up was 6.5 months. A total of 10 patients treated by enzalutamide progressed (43.47%) and eight patients died (34.78%). A total of five patients treated by abiraterone progressed (55.56%) and one patient died (11.11%). We did not observe any statistical difference in over all survival (HR 0.2362, 95% CI 0.0295– 1.8942; p = 0.102) and in progression-free survival (HR 0.9853, 95% CI 0.2934– 3.308; p = 0.939) between enzalutamide and abirateron.

Conclusion:
Our retrospective study demonstrated similar efficacy of enzalutamide and abiraterone in mCRPC patients previously treated by chemotherapy.

Key words:
prostate cancer – enzalutamide – abiraterone – overall survival – progression-free survival – toxicity – metastases

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted:
11. 11. 2015

Accepted:
11. 1. 2016

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [citováno 13. červenec 2009]. Verze 7.0 [2007]. Dostupný z: http:/ / www.svod.cz.

2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502– 1512.

3. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone plus prednisone for advanced refractory prostatae cancer. N Engl J Med 2004; 351(15): 1513– 1520.

4. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostatae cancer progressing after docetaxel treatment: a randimized open-label trial. Lancet 2010; 376(9747): 1147– 1154. doi: 10.1016/S0140-6736 (10)61389-X.

5. Sartor AO. Progression of metastatic castrate-resistant prostatae cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011; 4: 18. doi: 10.1186/1756-8722-4-18.

6. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2003; 10(1): 33– 39.

7. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer directed therapies targeting the androgen-receptor signaling axil. J Clin Oncol 2005; 23(32): 8253– 8261.

8. Ondruš D, Ondrušová M. Manažement pacientov s kastračne rezistentným metastatickým karcinómom prostaty. Klin Onkol 2015; 28(1): 24– 29. doi: 10.14735/amko201524.

9. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostatae cancer after chemotherapy. N Engj J Med 2012; 367(13): 1187– 1197.

10. de Bono JS, Logothesis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995– 2005. doi: 10.1056/NEJMoa1014618.

11. Dearden L, Misingarimi P, Shalet N et al. Real-world treatment with abirateron acetate in metatsatic castration-resistance prostate cancer (mCRPC) patiens in post-chemotherapy petting in Europe. The 18^th ECCO – 40^th ESMO European Cancer Congress, Vienna, 25.– 29. 9. 2015: abstr. 2545.

12. Tan PS, Haaland B, Montero AJ et al. Hormonal therapeutics enzalutamide and abirateron acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel – an indirection comparison. Clin Med Insights Oncol 2014; 8: 29– 36. doi: 10.4137/CMO.S13671.

13. Richards J, Lim AC, Hay CW et al. Interaction of abiraterone, epelrenone and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012; 72(9): 2176– 2182. doi: 10.1158/0008-5472.CAN-11-3980.

14. Luthy IA, Begin DJ, Labrie F. Androgenic acitivity of synthetic progestins and spironolactone in androgen-senzitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988; 31(5): 845– 852.

15. Taplin ME, Bubley GJ, Shuster TD et al. Mutation of the androgen receptor gene in metastatic androgen-receptor gene in metastatic androgen-independent prostatae cancer. N Engl J Med 1995; 332(21): 1393– 1398.

16. Sher HI, Fizazi K, Saad F et al. Association of baseline corticosteroid with outcomes in multivariate analysis of the phase 3 affirm study of enzalutamide (ENZA), an androgen receptor signaling inhibitorr (ARSI). In ESMO 2012, Vienna; abstr. 2887.

17. Ryan CJ, Smith MR, de Bono JS et al. Abirateron in metastatic prostatae cancer without previous chemotherapy. N Engl J Med 2013; 368(2): 138– 148. doi: 10.1056/NEJMoa1209096.

18. Beer TM, Amstrong AJ, Rathkof DE et al. Enzalutamide in metastatic prostatae cancer before chemotherapy. N Engl J Med 2014; 371(5): 424– 433. doi: 10.1056/NEJMoa1405095.

19. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamid and abirateron in prostate cancer. N Eng J Med 2014; 371(11): 1028– 1038. doi: 10.1056/NEJMoa1315815.